 Matthew Rossman
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 23 | 2023 | 1644 | 2.890 |
Why?
| | Aging | 16 | 2024 | 1618 | 2.320 |
Why?
| | Antioxidants | 6 | 2023 | 530 | 2.230 |
Why?
| | Leg | 15 | 2022 | 225 | 2.150 |
Why?
| | Endothelium, Vascular | 15 | 2023 | 843 | 2.110 |
Why?
| | Vasodilation | 18 | 2022 | 419 | 2.080 |
Why?
| | Nitric Oxide | 14 | 2023 | 823 | 1.730 |
Why?
| | Mitochondria | 5 | 2023 | 747 | 1.680 |
Why?
| | Oxidative Stress | 12 | 2023 | 1076 | 1.600 |
Why?
| | Brachial Artery | 7 | 2022 | 176 | 1.490 |
Why?
| | Vascular Stiffness | 8 | 2023 | 407 | 1.390 |
Why?
| | Muscle Fatigue | 5 | 2017 | 94 | 1.340 |
Why?
| | Vascular Diseases | 5 | 2023 | 230 | 1.330 |
Why?
| | Blood Vessels | 3 | 2020 | 180 | 1.210 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 72 | 1.210 |
Why?
| | Femoral Artery | 9 | 2016 | 167 | 1.040 |
Why?
| | Muscle, Skeletal | 15 | 2024 | 1472 | 1.030 |
Why?
| | Ascorbic Acid | 3 | 2021 | 110 | 1.010 |
Why?
| | Regional Blood Flow | 14 | 2022 | 424 | 0.990 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 913 | 0.970 |
Why?
| | Movement | 8 | 2022 | 244 | 0.960 |
Why?
| | Reactive Oxygen Species | 10 | 2023 | 531 | 0.870 |
Why?
| | Endothelial Cells | 7 | 2023 | 681 | 0.860 |
Why?
| | NAD | 1 | 2023 | 63 | 0.860 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 104 | 0.790 |
Why?
| | Citrulline | 1 | 2022 | 40 | 0.790 |
Why?
| | Cellular Senescence | 3 | 2023 | 152 | 0.780 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 29 | 0.760 |
Why?
| | Sodium Nitrite | 1 | 2021 | 37 | 0.730 |
Why?
| | Bronchi | 1 | 2022 | 231 | 0.710 |
Why?
| | Aged | 30 | 2023 | 19061 | 0.700 |
Why?
| | Stroke Volume | 4 | 2019 | 504 | 0.660 |
Why?
| | Exercise Tolerance | 5 | 2023 | 213 | 0.630 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 349 | 0.600 |
Why?
| | Dietary Supplements | 5 | 2023 | 460 | 0.600 |
Why?
| | Mitochondria, Muscle | 5 | 2021 | 93 | 0.590 |
Why?
| | Heating | 1 | 2017 | 17 | 0.580 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 1727 | 0.560 |
Why?
| | Muscle Contraction | 7 | 2021 | 389 | 0.530 |
Why?
| | Asthma | 2 | 2022 | 2029 | 0.510 |
Why?
| | Fatigue | 2 | 2014 | 294 | 0.500 |
Why?
| | Young Adult | 21 | 2023 | 10455 | 0.490 |
Why?
| | Humans | 57 | 2023 | 114623 | 0.480 |
Why?
| | Physical Endurance | 2 | 2013 | 232 | 0.470 |
Why?
| | Hyperemia | 5 | 2022 | 45 | 0.460 |
Why?
| | Heart | 1 | 2018 | 612 | 0.460 |
Why?
| | Vasoconstriction | 6 | 2022 | 177 | 0.460 |
Why?
| | Male | 40 | 2024 | 55554 | 0.440 |
Why?
| | Thioctic Acid | 1 | 2013 | 10 | 0.440 |
Why?
| | Nitrates | 3 | 2022 | 72 | 0.430 |
Why?
| | Vitamin E | 1 | 2013 | 110 | 0.420 |
Why?
| | Arteries | 4 | 2023 | 247 | 0.420 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 5 | 0.410 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 6 | 0.410 |
Why?
| | Knee | 1 | 2012 | 51 | 0.400 |
Why?
| | Resistance Training | 2 | 2023 | 113 | 0.380 |
Why?
| | Cross-Over Studies | 3 | 2023 | 440 | 0.380 |
Why?
| | Middle Aged | 17 | 2023 | 26719 | 0.370 |
Why?
| | Diet, Western | 2 | 2021 | 66 | 0.360 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 387 | 0.360 |
Why?
| | Female | 26 | 2023 | 59466 | 0.360 |
Why?
| | Healthy Volunteers | 4 | 2021 | 197 | 0.350 |
Why?
| | Oxygen Consumption | 7 | 2018 | 588 | 0.350 |
Why?
| | Exercise Test | 3 | 2022 | 544 | 0.350 |
Why?
| | Blood Pressure | 7 | 2023 | 1538 | 0.340 |
Why?
| | Adult | 21 | 2023 | 30528 | 0.320 |
Why?
| | Electromyography | 4 | 2014 | 326 | 0.320 |
Why?
| | Posture | 5 | 2016 | 152 | 0.320 |
Why?
| | Caloric Restriction | 2 | 2020 | 90 | 0.300 |
Why?
| | Atherosclerosis | 3 | 2018 | 341 | 0.300 |
Why?
| | Hand Strength | 3 | 2023 | 95 | 0.290 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 194 | 0.280 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 522 | 0.270 |
Why?
| | Motor Activity | 4 | 2024 | 640 | 0.260 |
Why?
| | Feedback, Physiological | 3 | 2014 | 68 | 0.250 |
Why?
| | Sympathetic Nervous System | 3 | 2023 | 171 | 0.240 |
Why?
| | Respiratory Muscles | 2 | 2023 | 28 | 0.240 |
Why?
| | Pulse Wave Analysis | 5 | 2023 | 207 | 0.230 |
Why?
| | Spermidine | 1 | 2024 | 17 | 0.230 |
Why?
| | Animals | 13 | 2024 | 31694 | 0.230 |
Why?
| | Flavonols | 1 | 2023 | 11 | 0.230 |
Why?
| | Arterial Pressure | 5 | 2019 | 99 | 0.230 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.220 |
Why?
| | Adolescent | 7 | 2023 | 17831 | 0.220 |
Why?
| | Vaping | 1 | 2023 | 45 | 0.210 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 128 | 0.210 |
Why?
| | Endothelin-1 | 2 | 2016 | 167 | 0.210 |
Why?
| | Acetylcholine | 2 | 2023 | 166 | 0.210 |
Why?
| | Treatment Outcome | 4 | 2022 | 9084 | 0.210 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 71 | 0.200 |
Why?
| | Hypertension | 2 | 2021 | 1056 | 0.200 |
Why?
| | Age Factors | 4 | 2016 | 2894 | 0.200 |
Why?
| | Administration, Oral | 2 | 2015 | 728 | 0.200 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.190 |
Why?
| | Breathing Exercises | 1 | 2021 | 18 | 0.190 |
Why?
| | Inhalation | 1 | 2021 | 26 | 0.190 |
Why?
| | Double-Blind Method | 3 | 2023 | 1660 | 0.190 |
Why?
| | Mice | 9 | 2024 | 14860 | 0.190 |
Why?
| | Inflammation | 5 | 2023 | 2477 | 0.190 |
Why?
| | Cardiovascular System | 3 | 2020 | 125 | 0.190 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 89 | 0.180 |
Why?
| | Dementia | 1 | 2023 | 187 | 0.180 |
Why?
| | Hypotension | 1 | 2022 | 116 | 0.180 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 10 | 0.170 |
Why?
| | Drug Monitoring | 1 | 2021 | 184 | 0.170 |
Why?
| | Biomarkers | 3 | 2021 | 3408 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2019 | 18 | 0.170 |
Why?
| | Glucose Intolerance | 1 | 2021 | 136 | 0.170 |
Why?
| | Supine Position | 2 | 2016 | 32 | 0.160 |
Why?
| | Models, Animal | 1 | 2021 | 344 | 0.160 |
Why?
| | Athletes | 1 | 2022 | 328 | 0.160 |
Why?
| | Energy Metabolism | 2 | 2021 | 731 | 0.160 |
Why?
| | Hemodynamics | 6 | 2023 | 1012 | 0.160 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 45 | 0.160 |
Why?
| | Coronary Circulation | 1 | 2019 | 133 | 0.160 |
Why?
| | Electron Transport | 1 | 2018 | 108 | 0.160 |
Why?
| | Fasting | 1 | 2020 | 240 | 0.150 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 253 | 0.150 |
Why?
| | Heart Rate | 6 | 2023 | 709 | 0.150 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.150 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 58 | 0.150 |
Why?
| | Habits | 1 | 2017 | 36 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 185 | 0.140 |
Why?
| | Coronary Vessels | 1 | 2019 | 227 | 0.140 |
Why?
| | Bicycling | 2 | 2021 | 86 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2018 | 195 | 0.140 |
Why?
| | Metabolomics | 1 | 2021 | 521 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 172 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2762 | 0.130 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 467 | 0.130 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 40 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 534 | 0.120 |
Why?
| | Reflex | 1 | 2015 | 64 | 0.120 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 66 | 0.120 |
Why?
| | Life Style | 1 | 2017 | 430 | 0.120 |
Why?
| | Muscle Strength | 3 | 2023 | 270 | 0.120 |
Why?
| | Cell Respiration | 3 | 2021 | 74 | 0.120 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 3 | 0.120 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 20 | 0.120 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 33 | 0.120 |
Why?
| | Bronchoconstriction | 1 | 2014 | 26 | 0.120 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 26 | 0.120 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 105 | 0.120 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 52 | 0.120 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 32 | 0.120 |
Why?
| | Shear Strength | 1 | 2014 | 65 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 445 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 358 | 0.110 |
Why?
| | Cardiac Output | 4 | 2015 | 143 | 0.110 |
Why?
| | Extremities | 1 | 2014 | 113 | 0.110 |
Why?
| | Vital Capacity | 1 | 2014 | 255 | 0.110 |
Why?
| | Recovery of Function | 1 | 2017 | 574 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 607 | 0.110 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 411 | 0.110 |
Why?
| | Free Radicals | 1 | 2013 | 99 | 0.110 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 86 | 0.110 |
Why?
| | Fentanyl | 3 | 2021 | 65 | 0.110 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 475 | 0.100 |
Why?
| | Single-Blind Method | 1 | 2013 | 258 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6344 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 239 | 0.100 |
Why?
| | Aorta | 3 | 2021 | 386 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 287 | 0.100 |
Why?
| | Central Nervous System | 1 | 2014 | 235 | 0.100 |
Why?
| | Mice, Inbred C57BL | 4 | 2024 | 4689 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 718 | 0.090 |
Why?
| | Knee Joint | 1 | 2014 | 323 | 0.090 |
Why?
| | Motor Neurons | 1 | 2013 | 212 | 0.090 |
Why?
| | Spinal Cord | 1 | 2013 | 347 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2019 | 3003 | 0.090 |
Why?
| | Sepsis | 1 | 2016 | 509 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4411 | 0.080 |
Why?
| | Biological Availability | 2 | 2021 | 119 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 1945 | 0.070 |
Why?
| | Photoplethysmography | 2 | 2016 | 15 | 0.060 |
Why?
| | Fingers | 2 | 2016 | 83 | 0.060 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 46 | 0.060 |
Why?
| | Respiratory Therapy | 1 | 2023 | 19 | 0.060 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 209 | 0.060 |
Why?
| | Time Factors | 3 | 2021 | 6112 | 0.050 |
Why?
| | Lower Extremity | 2 | 2019 | 335 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 184 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 112 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 51 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 320 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 218 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 771 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2021 | 101 | 0.050 |
Why?
| | Nicotine | 1 | 2023 | 265 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2021 | 85 | 0.050 |
Why?
| | Blood Circulation | 1 | 2021 | 35 | 0.050 |
Why?
| | Mouth | 1 | 2021 | 70 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 221 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 335 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 750 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 12542 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2021 | 180 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 225 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 2967 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 9 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 122 | 0.040 |
Why?
| | Oxygen | 1 | 2022 | 854 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 742 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 155 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 442 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2021 | 539 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 573 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 427 | 0.040 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 42 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 53 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 38 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 341 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 23 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 33 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1372 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1036 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 42 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 35 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1796 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 3881 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 647 | 0.030 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 21 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 822 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 31 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2017 | 350 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 117 | 0.030 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 24 | 0.030 |
Why?
| | Femoral Vein | 1 | 2012 | 28 | 0.030 |
Why?
| | Physical Exertion | 1 | 2014 | 209 | 0.030 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 59 | 0.030 |
Why?
| | Tryptophan | 1 | 2013 | 136 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2014 | 445 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2537 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4099 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 101 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 337 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 633 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 511 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 275 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 580 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3328 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 4894 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2507 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1528 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6217 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 8628 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2796 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4405 | 0.020 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|